Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma

CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma

“…Previous studies which randomized patients with aggressive NHL to receive CHOP (adriamycin: 50 mg/m 2 ) and CEOP (epirubicin: 50-70 mg/m 2 ) showed similar CR rates and projected survivals (OS and DFS) with both agents, but less cardiotoxicity with epirubicin. 10,11 In our study, CEOP (epirubicin: 60 mg/m 2 ) produced complete remission in 71 per cent of all patients. This is similar to CR rates in other single-centre trials using CHOP in aggressive lymphomas, where the CR rates ranged from 51-73 per cent.…”

CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma

“…Previous studies which randomized patients with aggressive NHL to receive CHOP (adriamycin: 50 mg/m 2 ) and CEOP (epirubicin: 50-70 mg/m 2 ) showed similar CR rates and projected survivals (OS and DFS) with both agents, but less cardiotoxicity with epirubicin. 10,11 In our study, CEOP (epirubicin: 60 mg/m 2 ) produced complete remission in 71 per cent of all patients. This is similar to CR rates in other single-centre trials using CHOP in aggressive lymphomas, where the CR rates ranged from 51-73 per cent.…”

A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin?s lymphoma: investigation of the current protocol through theoretical modelling results

“…This behavior is due to the low growth fraction of LG NHL cells. This result has been reflected in clinical studies: LG NHL patients are treated using a different protocol (Al-Ismail et al, 1987).…”

Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

“…Four ASCTs were performed for primary refractory disease, 11 for relapsed disease, and 2 for histological transformation in first remission. Before ASCT, 11 patients had a negative 18 F-FDG-PET-CT scan, 2 patients had a negative CT scan, 2 patients had a positive 18 34 7 DHAC 35 3 R-HyperCVAD 32 3 Hi-dICE 36 2 CHOP 37 2 DHAP 38 1 CNOP 39 1 RCHOP 31 1 R-CEOP 40 1 Bleomycin/vincristine 1 Rituximab/vinorelbine/gemcitabine 1 Cyclophosphamide/prednisolone 1 Rituximab 6 1 Fludarabine 1 Radiotherapy 3…”

CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma

“…Previous studies which randomized patients with aggressive NHL to receive CHOP (adriamycin: 50 mg/m 2 ) and CEOP (epirubicin: 50-70 mg/m 2 ) showed similar CR rates and projected survivals (OS and DFS) with both agents, but less cardiotoxicity with epirubicin. 10,11 In our study, CEOP (epirubicin: 60 mg/m 2 ) produced complete remission in 71 per cent of all patients. This is similar to CR rates in other single-centre trials using CHOP in aggressive lymphomas, where the CR rates ranged from 51-73 per cent.…”

A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin?s lymphoma: investigation of the current protocol through theoretical modelling results

“…This behavior is due to the low growth fraction of LG NHL cells. This result has been reflected in clinical studies: LG NHL patients are treated using a different protocol (Al-Ismail et al, 1987).…”

Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

“…Four ASCTs were performed for primary refractory disease, 11 for relapsed disease, and 2 for histological transformation in first remission. Before ASCT, 11 patients had a negative 18 F-FDG-PET-CT scan, 2 patients had a negative CT scan, 2 patients had a positive 18 34 7 DHAC 35 3 R-HyperCVAD 32 3 Hi-dICE 36 2 CHOP 37 2 DHAP 38 1 CNOP 39 1 RCHOP 31 1 R-CEOP 40 1 Bleomycin/vincristine 1 Rituximab/vinorelbine/gemcitabine 1 Cyclophosphamide/prednisolone 1 Rituximab 6 1 Fludarabine 1 Radiotherapy 3…”

CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma

“…Previous studies which randomized patients with aggressive NHL to receive CHOP (adriamycin: 50 mg/m 2 ) and CEOP (epirubicin: 50-70 mg/m 2 ) showed similar CR rates and projected survivals (OS and DFS) with both agents, but less cardiotoxicity with epirubicin. 10,11 In our study, CEOP (epirubicin: 60 mg/m 2 ) produced complete remission in 71 per cent of all patients. This is similar to CR rates in other single-centre trials using CHOP in aggressive lymphomas, where the CR rates ranged from 51-73 per cent.…”

A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin?s lymphoma: investigation of the current protocol through theoretical modelling results

“…This behavior is due to the low growth fraction of LG NHL cells. This result has been reflected in clinical studies: LG NHL patients are treated using a different protocol (Al-Ismail et al, 1987).…”

Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

“…Four ASCTs were performed for primary refractory disease, 11 for relapsed disease, and 2 for histological transformation in first remission. Before ASCT, 11 patients had a negative 18 F-FDG-PET-CT scan, 2 patients had a negative CT scan, 2 patients had a positive 18 34 7 DHAC 35 3 R-HyperCVAD 32 3 Hi-dICE 36 2 CHOP 37 2 DHAP 38 1 CNOP 39 1 RCHOP 31 1 R-CEOP 40 1 Bleomycin/vincristine 1 Rituximab/vinorelbine/gemcitabine 1 Cyclophosphamide/prednisolone 1 Rituximab 6 1 Fludarabine 1 Radiotherapy 3…”